Wei Chang An for Gastric Cancer

Wei Chang An and Gastric Cancer

A study was conducted to evaluate the effectiveness of Wei Chang An as a complementary and alternative therapy for gastric cancer patients with peritoneal metastasis. Between 2001 and 2012, 93 gastric cancer patients with peritoneal metastasis were enrolled in this study. The effect of traditional Chinese herbal medicine on their long-term outcome was investigated. Kaplan-Meier method was used to assess the difference in survival time, and Cox proportional hazards regression analysis was performed to identify independent prognostic factors. First-line chemotherapy plus traditional Chinese herbal medicine was performed in 47 patients and the other 46 patients received chemotherapy only. The overall survival was different between patients with and without traditional Chinese herbal medicine (12.0 versus 10.5 months; P=0.046). According to the Cox proportional hazard model, first-line chemotherapy cycle (hazards ratio [HR] = 0.527; 95% CI = 0.323-0.860) and TCHM (hazards ratio [HR] = 0.644; 95% CI = 0.481-0.992) were selected as independent prognostic factors for survival. The study suggested that traditional Chinese herbal medicine could improve the prognosis of the gastric cancer patients with peritoneal metastasis.

Wei Chang An

Radix Pseudostellariae 12 g

Rhizoma Atractylodis Macrocephalae 12 g

Pori  30 g

Rhizome Pinelliae Preparata 9 g)

Green Tangerine Peel 4.5 g

Concha Ostreae 30 g

Prunella vulgaris 9 g

Lu Zhao, Ai-Guang Zhao, Gang Zhao, Yan Xu,  Xiao-Hong Zhu,  Ni-Da Cao, Jian Zheng,  Jin-Kun Yang, and Jian-Hua Xu.  Survival Benefit of Traditional Chinese Herbal Medicine (A Herbal Formula for Invigorating Spleen) in Gastric Cancer Patients with Peritoneal Metastasis, Evidence-Based Complementary and Alternative Medicine Volume 2014, Article ID 625493,